Kindred Biosciences Inc

Kindred Biosciences — Investor Presentation (January 2017)

45 slides from Kindred Biosciences's investor presentation, Jan 6, 2017

  1. Slide 1: KindredBio

    1 KindredBio

  2. Slide 2: Forward Looking Statements

    2 KindredBio Forward Looking Statements This presentation contains forward-looking statements, including but not limited to statements regarding the timing of development for our product candidates, expected commencement and completion of pivotal trials, prospective product candidates, anticipated r

  3. Slide 3: Pets Are Family Members

    3 KindredBio Pets Are Family Members In 2015, pet owners in the U.S. spent $60.28 billion on pets Nearly 80 million U.S. households have a pet family member 40% of pets sleep in bed with the pet parents Source: APPA Pet Industry Market Size & Ownership Statistics 2015 The market is underappreciated

  4. Slide 4: We Love Our Pet Family Members

    4 KindredBio $15.7 billion on veterinary care $1.5 billion on dog knee surgeries $370 million on pet Halloween costumes $700 million on Valentine’s Day gifts Annually, U.S. pet parents spend: We Love Our Pet Family Members

  5. Slide 5: Millennials and Their Pets

    5 KindredBio Millennials and Their Pets 78% of Millennials and Boomers agree pets are Family 82% of Millennials feel getting a pet is part of preparing for a family, while only 59% of Boomers felt the same. Source: Pet Age, 2014: http://www.petage.com/the-millennial-mind/

  6. Slide 6: KindredBio's Strategy: Repurpose Human Drugs for Pets

    6 KindredBio KindredBio’s Strategy: Repurpose Human Drugs for Pets Pursue molecules already known to work Reduce technical risk Reduce timelines $3M-$5M to develop each pet drug Reduce financing risk Portfolio approach

  7. Slide 7: KindredBio Highlights

    7 KindredBio KindredBio Highlights Two launches by 2017 Zimeta™ for fever in horses Mirataz™ for mgmt. of weight loss in cats ~2 launches per year thereafter Attractive Markets Rapidly growing Few current competitors World Class Team Extensive drug development experience Human and veterinary experie

  8. Slide 8: World Class Leadership Team

    8 KindredBio Richard Chin, M.D. Founder and Chief Executive Officer Former Head of Clinical Research, BioTherapeutics, Genentech Rhodes Scholar World Class Leadership Team Denise Bevers​ Founder and Chief Operating Officer Founder, SD Scientific; 25 years in biotech/pharma Stephen Sundlof, D.V.M, Ph

  9. Slide 9: Deep Product Pipeline

    9 KindredBio Deep Product Pipeline Not all programs are listed. Some are not disclosed for competitive reasons. * Initial pilot studies completed. Final formulation being developed. Molecule Indication Discovery/Process Development Pilot/Pivotal Clinical Studies NADA & Launch Preparation Biologic Pr

  10. Slide 10: Market Opportunity

    10 KindredBio Market Opportunity

  11. Slide 11: Veterinary Market is Growing Rapidly

    11 KindredBio Veterinary Market is Growing Rapidly The veterinary care market grew 71% from 2006 to 2016 Animal health stocks have increased 35% in 2016, versus S&P 500 at 8.3% (as of Aug 2016, Reuters) Source: APPA Pet Industry Market Size & Ownership Statistics 2016 & TriMark Vet Health Market, Ju

  12. Slide 12: There is a High Willingness to Pay

    12 KindredBio Pet owners are willing to spend on their seriously ill pets if they require medical treatment. There is a High Willingness to Pay… $500 $1,000 $2,000 $5,000 Extremely/Very likely 62% 42% 35% 22% Somewhat likely 18% 20% 28% 20% Not too likely/Not at all likely 18% 36% 36% 55% Don’t know

  13. Slide 13: But Treatment Options are Limited

    13 KindredBio …But Treatment Options are Limited Underserved market with attractive growth opportunities Few competing biotechs Large pharma focused on blockbusters On average, less than a dozen pet drugs are approved annually by the FDA In 2016 the FDA approved: 6 novel pet drugs 22 novel humans dr

  14. Slide 14: Programs

    14 KindredBio Programs

  15. Slide 15: KindredBio Drug Development Process

    15 KindredBio KindredBio Drug Development Process Small Molecules Biologics Already validated in humans & established manufacturing Customize species- specific dosage and formulate flavored/convenient delivery Targets based on approved human drugs (e.g., Enbrel and Orencia) Create canine/ feline/equ

  16. Slide 16: Zimeta (dipyrone injection)

    16 KindredBio Zimeta™ (dipyrone injection) IV and Oral drug for the control of pyrexia (fever) in horses High unmet medical need U.S. equine Veterinarians report seeing 12 cases (median) of fever in a typical month Currently, no FDA-approved treatment for fever in horses Source: The Economic Impact

  17. Slide 17: Zimeta Development Program

    17 KindredBio Zimeta Development Program IV: NADA technical sections filed Effectiveness technical section of NADA approved by FDA Oct 2016 Expect approval 2H/2017, if review proceeds as expected Oral: Initial pilot studies completed Final formulation development underway

  18. Slide 18: Zimeta Pilot Study Results (IV)

    18 KindredBio Zimeta Pilot Study Results (IV) Mean Temp. over Time - First Dose and Crossover Dose (Treated Pts.) Zimeta

  19. Slide 19: Zimeta Pivotal Field Study Results (IV)

    19 KindredBio Zimeta Pivotal Field Study Results (IV) KB0120 study: Randomized, double-blind, placebo-controlled (N=130) Primary endpoint was improvement or resolution of fever Suc c e s s R a te (% ) P-value <0.0001 76.8 19.4 Placebo N=31 Zimeta N=99

  20. Slide 20: Zimeta New Product Opportunity

    20 KindredBio Zimeta New Product Opportunity Source: Zimeta Pricing Research, Ipsos Ag & Animal Health, May 2016 (n=160 U.S. equine Veterinarians) . Data on file at Kindred Biosciences. 88% of Veterinarians would seek information on a new product labeled for treatment of pyrexia Currently, there are

  21. Slide 21: Zimeta New Product Opportunity

    21 KindredBio Zimeta New Product Opportunity Industry adoption expected to be rapid Source: Zimeta Pricing Research, Ipsos Ag & Animal Health, May 2016 (n=160 U.S. equine Veterinarians) . Data on file at Kindred Biosciences. 95% believe Zimeta is a good fit for their practice 83% would use Zimeta in

  22. Slide 22: Mirataz (mirtazapine 2% transdermal ointment)

    22 KindredBio Mirataz™ (mirtazapine 2% transdermal ointment) Transdermal drug for the management of weight loss in cats Innovative Accusorb™ transdermal technology High unmet medical need Currently no FDA approved product is available 90% of Veterinarians treat cats with inappetence (avg. 7 cats/wee

  23. Slide 23: Mirataz Development Program

    23 KindredBio Mirataz Development Program Positive pivotal field study completed CMC technical section of NADA filed May 2016 Effectiveness technical section of NADA filed Aug 2016 Safety technical section of NADA filed Sep 2016 Expect approval 2H/2017 if review proceeds as expected

  24. Slide 24: Mirataz Pivotal Field Study Results

    24 KindredBio Mirataz Pivotal Field Study Results Randomized, double-blind, placebo-controlled study (N=231) Primary endpoint was percentage change in body weight from Day 1 to Week 2 Mean body weight c h ang e fro m D a y 1 to W ee k 2 (% ) n: 90 p-value: <0.0001 P-value <0.0001 4.07 0.29 Placebo N

  25. Slide 25: Mirataz New Product Opportunity

    25 KindredBio Mirataz New Product Opportunity Source:2016 U.S. Veterinarian Mirtazapine Phase 3 Research, Ipsos, September 2016 (n=201 U.S. small animal Veterinarians). Data on file at Kindred Biosciences. There are no FDA-approved products labeled for the control of weight loss in cats. Mirtazapine

  26. Slide 26: Mirataz New Product Opportunity

    26 KindredBio Mirataz New Product Opportunity The majority of Veterinarians would replace most or all of the mirtazapine they are using today with the transdermal mirtazapine gel formulation. Source:2016 U.S. Veterinarian Mirtazapine Phase 3 Research, Ipsos, September 2016 (n=201 U.S. small animal V

  27. Slide 27: Mirataz New Product Opportunity

    27 KindredBio Mirataz New Product Opportunity Source:2016 U.S. Veterinarian Mirtazapine Phase 3 Research, Ipsos, September 2016 (n=201 U.S. small animal Veterinarians). Data on file at Kindred Biosciences. 49% of Veterinarians report that ease of administering the medication and/or client medication

  28. Slide 28: Mirataz New Product Opportunity

    28 KindredBio Mirataz New Product Opportunity Source:2016 U.S. Veterinarian Mirtazapine Phase 3 Research, Ipsos, September 2016 (n=201 U.S. small animal Veterinarians). Data on file at Kindred Biosciences. Veterinarian adoption of Mirataz is expected to be rapid; 95% of Veterinarians would use Mirat

  29. Slide 29: Biologics

    29 KindredBio Biologics Highly experienced biologics team Extensive experience developing Lucentis®, Xolair®, Tysabri®, Avastin®, Rituxan®, Herceptin®, Enbrel®, and multiple other biologics Internal caninization/felinization/equinization expertise Promising biologics candidates Feline erythropoietin

  30. Slide 30: KIND-510: Feline Erythropoietin

    30 KindredBio KIND-510: Feline Erythropoietin Proprietary recombinant feline erythropoietin (epoCat™) Strong internal expertise in erythropoietin biology and engineering Initial laboratory study completed - positive efficacy signal, as evidenced by increased reticulocyte formation Pilot field study

  31. Slide 31: KIND-511: Anti-TNF for Newborn Foals

    31 KindredBio KIND-511: Anti-TNF for Newborn Foals Sick newborn foals are challenging and difficult to treat Approximately 50% mortality Pilot field study for Anti-Tumor Necrosis Factor (Anti-TNF) underway Sick foals defined as sepsis score ≥ 11 or positive blood culture Of 5 foals enrolled, all sur

  32. Slide 32: Key Focus Area: Atopic Dermatitis

    32 KindredBio Key Focus Area: Atopic Dermatitis Atopic dermatitis is a large market Apoquel® projected peak sales >$200M Multiple antibody candidates Anti-IgE antibody Anti-IL17a antibody Anti-IL4Ra antibody Anti-IL31 antibody Anti-CD20 antibody Multi-center, pilot field study underway to assess saf

  33. Slide 33: Key Focus Area: Cancer

    33 KindredBio Key Focus Area: Cancer Multiple antibody candidates Anti-CTLA4 antibody Anti-PD1 antibody Anti-PDL1 antibody Anti-CD20 antibody

  34. Slide 34: Biologics Manufacturing Plant

    34 KindredBio Biologics Manufacturing Plant In-house biologics manufacturing plant nearly complete Single-use, state of the art system Will allow full GMP commercial production of feline epo (epoCat™) Will allow full GMP clinical and early commercial production of antibodies

  35. Slide 35: Commercialization

    35 KindredBio Commercialization

  36. Slide 36: Commercialization

    36 KindredBio Commercialization Equine Commercialization: Launch and commercialize our U.S. products with ~10 person direct sales force Dog/Cat Commercialization Options: Self-Commercialization Out-license Partner for 3 – 5 years, and then transition to KindredBio salesforce

  37. Slide 37: Low Generic Penetration

    37 KindredBio Few pet generic companies No automatic substitution Requires sales & marketing effort Rimadyl reached peak sales several years after loss of exclusivity Relationship-oriented industry Low Generic Penetration Note: Companion Animal dispensing rate within the veterinary clinic. Source: I

  38. Slide 38: Exclusivity and IP Position

    38 KindredBio Exclusivity and IP Position Full intellectual property protection anticipated for antibody portfolio Use and formulation patents for small molecules 20 years of patent protection from date of filing Regulatory Exclusivity 5 years in U.S. 10 years in E.U. Lifecycle Management New formul

  39. Slide 39: Business Development

    39 KindredBio Business Development In active discussions about acquisitions of businesses and/or assets, particularly of equine assets Ideal candidate: Revenue generating/accretive Commercial infrastructure Complementary assets

  40. Slide 40: Financials

    Financials 40 KindredBio QQ),

  41. Slide 41: Select Summary Financials

    41 KindredBio Select Summary Financials $ millions For the quarter ended September 30, 2016 Operating expenses: Research and development $3.8 General and administrative $2.0 Total cash operating expenses (excluding stock-based compensation) $4.8 Total operating expenses (including stock-based compen

  42. Slide 42: Share Structure & Stock History

    42 KindredBio Share Structure & 6 Month Stock History 19.9 M Shares Outstanding 3.6 M Options1 US$107.4 M Market Cap2 US$58.7 M Working Capital3 1 As of September 30, 2016; avg. $6.35 2 As of close of market October 31, 2016 3 As of September 30, 2016 Analyst Coverage Alex Arfaei, BMO Capital Market

  43. Slide 43: Our Track Record

    43 KindredBio Our Track Record Founded the company in 2012 IPO in 2013 Assembled world-class team of human and animal health drug developers Two drugs submitted to the FDA for approval within 4 years since founding KindredBio (vs. average of 15 years in human drug development) Developed deep pipelin

  44. Slide 44: Summary

    44 KindredBio Summary Validated Drugs and Targets $3M-$5M to Market Multiple Approvals Starting within 1 year World Class Team

  45. Slide 45: Thank You

    Thank You Kindred Bio). tan KindredBio EQUINE KindredBioS KindredBio QQ),

Kindred Biosciences — Investor Presentation (January 2017) on 6ix